Oragenics announces completion of enrollment for ProBiora3 clinical trial

TAMPA, Florida--Florida-based biopharmaceutical company Oragenics has announced completion of the enrollment of the company's latest ProBiora3 human clinical study.

The company will sponsor the University of Washington School of Dentistry to conduct a 12-week, double-blind, placebo-controlled, randomized clinical study on ProBiora3. The study will assess various microbiological, cosmetic and oral health indices on approximately 50 healthy subjects to further substantiate the benefits of ProBiora3.

ProBiora3 is the result of more than 25 years of research and is the active ingredient in Oragenics’ Evora brand of oral health products. ProBiora3 is a patented blend of three strains of beneficial bacteria that are naturally found in healthy mouths.

“The University of Washington conducts a wide range of research in oral clinical sciences and fosters productive interactions with leaders in the health care industry,” said Dr. Linda LeResche, associate dean for Research at the UW School of Dentistry.

“Probiotics are an intriguing field of study in oral health, and we are pleased that Dr. Whasun ‘Sun’ Oh Chung, research associate pofessor in the Department of Oral Health Sciences, is participating as principal investigator of this Oragenics-funded clinical trial in our Regional Clinical Dental Research Center.”

John N. Bonfiglio, PhD., Oragenics chief executive officer, commented: “Oragenics is pleased to engage in this ProBiora3 clinical trial in collaboration with the University of Washington. We expect that these data will corroborate previous positive results obtained from human and animal studies conducted by both Oragenics and independent investigators. We also believe this study will reinforce the claim that ProBiora3, the active ingredient in EvoraPlus and EvoraPro, promotes oral health by helping to maintain a naturally balanced oral microflora.”

The company anticipates that the study will provide additional evidence that the probiotics in ProBiora3 can inhibit those organisms of the oral cavity that have been previously associated with bad breath.

For more information, visit www.oragenics.com.

To comment on this topic, go to http://community.pennwelldentalgroup.com.